Trial · NCT06613100
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants who Experienced Treatment-emergent Adverse Events | Up to 45 months | Inclusive of adverse events, serious adverse events, and changes in vital signs and clinical laboratory tests. |
| Primary | Number of Participants who Experienced Treatment-related Adverse Events | Up to 28 months | |
| Primary | Number of Participants who Received Radical Prostatectomy After Completing Xaluritamig Treatment | Up to 25 months | |
| Primary | Number of Participants who Experienced Complications of Radical Prostatectomy According to Clavien-Dindo Classification | Up to 28 months | |
| Secondary | Change in Prostate-specific Antigen (PSA) Levels from Baseline to End of Xaluritamig Treatment | Up to 25 months | |
| Secondary | Prostate Imaging-Reporting and Data System (PI-RADS) Score | Up to 25 months | |
| Secondary | Pathological Complete Response (pCR) Following Radical Prostatectomy | Up to 25 months | |
| Secondary | Minimal Residual Disease (MRD) | Up to 25 months | |
| Secondary | Number of Participants who Rise to PSA ≥ 0.2 ng/mL Post-radical Prostatectomy | Up to 45 months | |
| Secondary | Time to PSA Rise ≥ 0.2 ng/mL Post-radical Prostatectomy | Up to 45 months | |
| Secondary | Undetectable PSA at SFU | Up to 26 months | |
| Secondary | PSA Progression-free Survival | Up to 45 months | |
| Secondary | Maximum Serum Concentration (Cmax) of Xaluritamig | Up to 45 months | |
| Secondary | Time to Maximum Concentration (Tmax) of Xaluritamig | Up to 45 months | |
| Secondary | Area Under the Concentration Time Curve (AUC) Over the Dosing Interval | Up to 45 months | |
| Secondary | Accumulation Following Multiple Dosing | Up to 45 months | |
| Secondary | Half-life (t1/2) of Xaluritamig | Up to 45 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06613100/registered